PMID- 38539310
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 2227-9067 (Print)
IS  - 2227-9067 (Electronic)
IS  - 2227-9067 (Linking)
VI  - 11
IP  - 3
DP  - 2024 Feb 23
TI  - Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for 
      Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD).
LID - 10.3390/children11030275 [doi]
LID - 275
AB  - Metabolic-dysfunction-associated steatotic liver disease (MASLD) is the most 
      common liver disease in children in the US and, if untreated, may progress to 
      end-stage liver disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) 
      have shown improvement in MASLD markers in adults with type 2 diabetes mellitus 
      (T2DM). Currently, there is a lack of medications available for the treatment of 
      pediatric MASLD. We aimed to provide preliminary data on the effects of GLP-1 RAs 
      on markers of MASLD in a retrospective study, in an effort to bridge this gap in 
      the pharmacotherapies available. Nine patients from a T2DM clinic who met the 
      following inclusion criteria were included in this study: patients diagnosed with 
      pre-diabetes or T2DM, prescribed a GLP-1 RA in the prior 12 months, and having 
      alanine aminotransferase (ALT) elevated to twice the upper limit of the normal 
      range, indicating evidence of MASLD. The average change between baseline and the 
      first measurement after starting a GLP-1 RA was calculated for ALT, hemoglobin 
      A1c, and BMI. ALT decreased by an average of 98 points. A1c decreased by an 
      average of 2.2 points. BMI decreased by an average of 2.4 points. There was 
      greater reduction in ALT and A1c compared to BMI, suggesting that improvement in 
      MASLD may be independent of weight loss. This is a preliminary study that shows 
      potential, and prospective studies are needed to evaluate the effects of GLP-1 
      RAs in the management of pediatric MASLD.
FAU - Choi, Erika
AU  - Choi E
AD  - Division of Endocrinology, Department of Pediatrics, Emory University, Atlanta, 
      GA 30322, USA.
AD  - Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.
FAU - Ramirez Tovar, Ana
AU  - Ramirez Tovar A
AUID- ORCID: 0000-0002-9038-6589
AD  - Department of Pediatrics, Division of Gastroenterology, Hepatology, and 
      Nutrition, Emory University, Atlanta, GA 30322, USA.
FAU - He, Zhulin
AU  - He Z
AUID- ORCID: 0000-0002-5852-8065
AD  - Pediatric Biostatistics Core, Emory University, Atlanta, GA 30322, USA.
FAU - Soler Rodriguez, Dellys M
AU  - Soler Rodriguez DM
AD  - Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.
AD  - Department of Pediatrics, Division of Gastroenterology, Hepatology, and 
      Nutrition, Emory University, Atlanta, GA 30322, USA.
FAU - Vos, Miriam B
AU  - Vos MB
AD  - Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.
AD  - Department of Pediatrics, Division of Gastroenterology, Hepatology, and 
      Nutrition, Emory University, Atlanta, GA 30322, USA.
FAU - Arora, Shruthi
AU  - Arora S
AD  - Division of Endocrinology, Department of Pediatrics, Emory University, Atlanta, 
      GA 30322, USA.
AD  - Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.
FAU - Fadoju, Doris
AU  - Fadoju D
AD  - Division of Endocrinology, Department of Pediatrics, Emory University, Atlanta, 
      GA 30322, USA.
AD  - Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.
LA  - eng
PT  - Journal Article
DEP - 20240223
PL  - Switzerland
TA  - Children (Basel)
JT  - Children (Basel, Switzerland)
JID - 101648936
PMC - PMC10969291
OTO - NOTNLM
OT  - ALT
OT  - GLP-1
OT  - MASLD
OT  - liver steatosis
OT  - obesity
COIS- Dr. Miriam B Vos has served as a consultant for Boehringer Ingelheim 
      Corporations, Intercept Pharmaceuticals, Inc., Novo Nordisk Pharmaceuticals, 
      Thiogenesis Therapeutics, Thetis, and Prosciento.
EDAT- 2024/03/28 06:45
MHDA- 2024/03/28 06:46
PMCR- 2024/02/23
CRDT- 2024/03/28 01:01
PHST- 2023/12/22 00:00 [received]
PHST- 2024/02/15 00:00 [revised]
PHST- 2024/02/20 00:00 [accepted]
PHST- 2024/03/28 06:46 [medline]
PHST- 2024/03/28 06:45 [pubmed]
PHST- 2024/03/28 01:01 [entrez]
PHST- 2024/02/23 00:00 [pmc-release]
AID - children11030275 [pii]
AID - children-11-00275 [pii]
AID - 10.3390/children11030275 [doi]
PST - epublish
SO  - Children (Basel). 2024 Feb 23;11(3):275. doi: 10.3390/children11030275.